NKGen Biotech, Inc. NKGN
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.46% | -- | -- | -- | 68.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.45% | -- | -- | -- | 21.61% |
| Operating Income | 21.45% | -- | -- | -- | -21.80% |
| Income Before Tax | 70.63% | -- | -- | -- | -180.60% |
| Income Tax Expenses | 657.14% | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | 70.56% | -- | -- | -- | -180.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.56% | -- | -- | -- | -180.56% |
| EBIT | 21.45% | -- | -- | -- | -21.80% |
| EBITDA | 22.43% | -- | -- | -- | -22.97% |
| EPS Basic | 82.70% | -- | -- | -- | -56.81% |
| Normalized Basic EPS | 58.72% | -- | -- | -- | -16.16% |
| EPS Diluted | 73.48% | -- | -- | -- | -56.96% |
| Normalized Diluted EPS | 56.47% | -- | -- | -- | -16.16% |
| Average Basic Shares Outstanding | 97.99% | -- | -- | -- | 69.95% |
| Average Diluted Shares Outstanding | 195.95% | -- | -- | -- | 69.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |